PLOD1 and polycystic ovary syndrome: With longer terminal half-life time, MVT-602, a novel KISS1R agonist, has longer duration of kisspeptin targeted action of stimulating GnRH synthesis and sustaining peak GnRH levels, consequently promoting LH synthesis in women with PCOS.